Retraction note Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene (Journal of Biomedical Science, (2014), 21, 1, (19), 10.1186/1423-0127-21-19);Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: Effects of serenoa repens, selenium and lycopene

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Minutoli, Letteria ^a   Altavilla, Domenica ^b   Marini, Herbert ^a   Rinaldi, Mariagrazia ^a   Irrera, Natasha ^a   Pizzino, Gabriele ^a   Bitto, Alessandra ^a   Arena, Salvatore ^b   Cimino, Sebastiano ^c   Squadrito, Francesco ^a   Russo, Giorgio Ivan ^c   Morgia, Giuseppe ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Apoptosis; BPH; IAPs; Lycopene; Selenium; Serenoa Repens

Indexed keywords

CASPASE 3; HERBACEOUS AGENT; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERLEUKIN 6; LYCOPENE; MESSENGER RNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SELENIUM; SURVIVIN; TESTOSTERONE; TESTOSTERONE PROPIONATE; APOPTOSIS REGULATORY PROTEIN; CAROTENOID; INHIBITOR OF APOPTOSIS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE WEIGHT; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SABAL; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; PATHOLOGY; PHYTOTHERAPY;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CAROTENOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; RATS; SERENOA;

EID: 84899085270     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-024-01066-x     Document Type: Erratum

References (28)

1. Apoptosis: a gene-directed programme of cell death. Alison MR, Sarraf CE, J R Coll Physicians Lond 1992 26 25 35 1315390
2. Programmed cell death in animal development and disease. Fuchs Y, Steller H, Cell 2011 147 742 758 10.1016/j.cell.2011.10.033 22078876
3. Dietary patterns and prostatic diseases. Sebastiano C, Vincenzo F, Tommaso C, Giuseppe S, Marco R, Ivana C, Giorgio R, Massimo M, Giuseppe M, Front Biosci (Elite Ed) 2012 4 195 204 Review 22201864
4. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative comparative study of phytotherapy and watchful waiting. Djavan B, Fong YK, Chaudry A, Reissigl A, Anagnostou T, Bagheri F, Waldert M, Fajkovic H, Marihart S, Harik M, Spaller S, Remzi M, World J Urol 2005 23 253 256 10.1007/s00345-005-0005-7 16175413
5. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cell accumulation and glandular epithelium trophism in the rat prostate. Mitropoulos D, Kyroudi A, Zervas A, Papadoukakis S, Giannopoulos A, Kittas C, Karayannacos P, World J Urol 2002 19 457 461 12022715
6. Polyphenols: key issues involved in chemoprevention of prostate cancer. Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, Morgia G, Oxid Med Cell Longev 2012 2012 632959 22690272
7. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. Fourcade RO, Lacoin F, Roupret M, Slama A, Le Fur C, Michel E, Sitbon A, Cotte FE, World J Urol 2012 30 419 426 10.1007/s00345-011-0756-2 21892656
8. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Roehrborn CG, Med Clin North Am 2011 95 87 100 10.1016/j.mcna.2010.08. 013 21095413
9. Potential efficacy of some african plants in benign prostatic hyperplasia and prostate cancer. Russo GI, Cimino S, Salamone C, Madonia M, Favilla V, Castelli T, Morgia G, Mini Rev Med Chem 2013 13 1564 1571 23713889
10. IAPs: more than just inhibitors of apoptosis proteins. Dubrez-Daloz L, Dupoux A, Cartier J, Cell Cycle 2008 7 1036 1046 10.4161/cc.7.8.5783 18414036
11. Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate. Rodriguez-Berriguete G, Fraile B, de Bethencourt FR, Prieto-Folgado A, Bartolome N, Nunez C, Prati B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M, BMC Cancer 2010 10 18 10.1186/1471-2407-10-18 20078866
12. Serenoa repens for benign prostatic hyperplasia. Tacklind J, MacDonald R, Rutks I, Wilt TJ, Cochrane Database Syst Rev 2009 2 D001423 19370565
13. Effects of Serenoa repens, selenium and lycopene (Profluss(R)) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G, Masieri L, Minutoli L, Grosso G, Castelli T, Int Braz J Urol 2013 39 214 221 23683667
14. The combination of Serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth. Altavilla D, Bitto A, Polito F, Irrera N, Marini H, Arena S, Favilla V, Squadrito F, Morgia G, Minutoli L, J Urol 2011 186 1524 1529 10.1016/j.juro.2011.05.049 21855911
15. Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Pandita RK, Persson K, Hedlund P, Andersson KE, Prostate 1998 35 102 108 10.1002/(SICI)1097-0045(19980501)35: 2<102::AID-PROS3>3.0.CO;2-L 9568673
16. Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Bonvissuto G, Minutoli L, Morgia G, Bitto A, Polito F, Irrera N, Marini H, Squadrito F, Altavilla D, Urology 2011 77 248e9 248e16
17. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. Vela-Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C, J Urol 2005 173 507 510 10.1097/01.ju.0000150533. 94952.25 15643230
18. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Hostanska K, Suter A, Melzer J, Saller R, Anticancer Res 2007 27 873 881 17465214
19. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Kandas NO, Randolph C, Bosland MC, Nutr Cancer 2009 61 251 264 10.1080/01635580802398430 19235042
20. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. Wright CW, Duckett CS, J Clin Invest 2005 115 2673 2678 10.1172/JCI26251 16200201
21. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV, Cell 1995 83 1243 1252 10.1016/0092-8674(95)90149-3 8548810
22. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr, Science 1998 281 1680 1683 9733516
23. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Chamaillard M, Girardin SE, Viala J, Philpott DJ, Cell Microbiol 2003 5 581 592 10.1046/j.1462-5822.2003.00304.x 12925128
24. Integrity of ATP binding site is essential for effective inhibition of the intrinsic apoptosis pathway by NAIP. Karimpour S, Davoodi J, Ghahremani MH, Biochem Biophys Res Commun 2011 407 158 162 10.1016/j.bbrc.2011.02.130 21371431
25. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng SC, Neoplasia 2000 2 235 241 10935509
26. Targeting survivin in cancer therapy. Pennati M, Folini M, Zaffaroni N, Expert Opin Ther Targets 2008 12 463 476 10.1517/14728222.12.4.463 18348682
27. Molecular and cellular pathogenesis ofbenign prostatic hyperplasia. Lee KL, Peehl Donna M, J Urol 2004 172 1784 1791 10.1097/01.ju.0000133655.71782.14 15540721
28. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L, Prostate 2011 71 736 747 10.1002/pros.21289 20945403